TABLE 3.
miR‐155‐centered immune response genes
| Gene | R* | S* | p | Description |
|---|---|---|---|---|
| IFI27 | 24,288 | 74,040 | 0.01 | Interferon, alpha‐inducible protein 27 [NM_005532] |
| NUPL2 | 23,926 | 16,295 | 0.01 | Nucleoporin like 2 [ENST00000477844] |
| TLR5 | 8531 | 22,005 | 0.01 | Toll‐like receptor 5 [NM_003268] |
| INPP5D | 6121 | 1641 | 0.03 | Inositol polyphosphate 5‐phosphatase, 145 kDa, [NM_001017915] |
| CD81 | 3943 | 1752 | 0.01 | CD81 molecule [NM_004356] |
| ICAM3 | 3720 | 1625 | <0.01 | Intercellular adhesion molecule 3 [NM_002162] |
| LGALS9 | 1502 | 3237 | 0.01 | Lectin, galactoside‐binding, soluble, 9 [ENST00000584386] |
| ERBB2 | 1203 | 2528 | 0.01 | V‐erb‐b2 avian erythroblastic leukemia viral oncogene homolog 2 [NM_001005862] |
| ICAM1 | 1888 | 586 | 0.02 | Intercellular adhesion molecule 1 [NM_000201] |
| WASL | 593 | 1378 | <0.01 | Wiskott‐Aldrich syndrome like [NM_003941] |
| CDH1 | 367 | 1529 | 0.01 | Cadherin 1, type 1, E‐cadherin (epithelial) [NM_004360] |
| JAK3 | 1073 | 526 | <0.01 | Janus kinase 3 [NM_000215] |
| PRKAR1A | 781 | 459 | 0.01 | Protein kinase, cAMP‐dependent, regulatory, type I, alpha, [NM_212472] |
| MAP3K14 | 665 | 393 | 0.03 | Mitogen‐activated protein kinase kinase kinase 14 [NM_003954] |
| CBL | 527 | 386 | 0.02 | Cbl proto‐oncogene, E3 ubiquitin protein ligase [NM_005188] |
| STAT3 | 596 | 254 | 0.01 | Signal transducer and activator of transcription 3 (acute phase response factor) [NM_213662] |
| PIK3CD | 555 | 267 | 0.01 | Phosphatidylinositol 4,5‐bisphosphate 3‐kinase, catalytic subunit delta [NM_005026] |
| KPNA7 | 161 | 611 | <0.01 | Karyopherin alpha 7 (importin alpha 8) [NM_001145715] |
| DOCK1 | 328 | 405 | 0.02 | Dedicator of cytokinesis 1 [NM_001380] |
| CXADR | 121 | 482 | <0.01 | Coxsackie virus and adenovirus receptor [NM_001338] |
| TLR3 | 140 | 419 | 0.01 | Toll‐like receptor 3 [NM_003265] |
| BTC | 124 | 417 | <0.01 | Betacellulin [NM_001729] |
| STAT5A | 396 | 129 | 0.01 | Signal transducer and activator of transcription 5A [NM_003152] |
| MAP3K13 | 145 | 265 | 0.02 | Mitogen‐activated protein kinase kinase kinase 13, [NM_004721] |
| ERBB3 | 84 | 294 | <0.01 | V‐erb‐b2 avian erythroblastic leukemia viral oncogene homolog 3, [NM_001005915] |
| HAVCR2 | 272 | 66 | 0.01 | Hepatitis A virus cellular receptor 2 [NM_032782] |
| PRKCB | 235 | 83 | 0.01 | Protein kinase C, beta, [NM_002738] |
| CNPY3 | 202 | 93 | <0.01 | Canopy FGF signaling regulator 3 [NM_006586] |
| TRIM32 | 98 | 68 | 0.04 | Tripartite motif‐containing 32 [NM_012210] |
| CTLA4 | 111 | 33 | 0.04 | Cytotoxic T‐lymphocyte‐associated protein 4 [NM_005214] |
| FGF7 | 85 | 42 | 0.05 | Fibroblast growth factor 7[NM_002009] |
| NOD1 | 62 | 25 | <0.01 | Nucleotide‐binding oligomerization domain‐containing 1 [NM_006092] |
Abbreviation: HPET: H. pylori eradication therapy.
*
The Table lists 32 genes that are differentially expressed between HPET‐resistant (R) and HPET‐sensitive (S) gastric diffuse large B‐cell lymphomas. Genes with high expression levels are at the top.